Filed with ASX · · 12 pages · English
The report highlights the activation of multiple trial sites for the PROTECT-MI Phase IIa clinical trial and the recruitment of patients, with expectations for accelerated enrollment as more sites come online. Additionally, the company received positive feedback from the US FDA regarding its pre-IND submission for Xolatryp, supporting its development as a treatment for heart attack-related injuries. Nyrada reported a strong cash position, with significant funds raised through a placement and plans for a Securities Purchase Plan to further bolster its financial resources.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Page 1 Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818 19 October 2026 Sydney, Australia Nyrada Quarterly Activities Report & Appendix 4C Highlights: • Four hospitals activated and screening in the PROTECT-MI Phase IIa clinical trial, with a...
Follow Nyrada into a list and get an email when it puts out news.
Follow Nyrada